|
Gender, n (%)
| | | | |
|
Male
|
811 (63)
|
297 (62)
|
985 (63)
|
123 (60)
|
|
Female
|
486 (37)
|
183 (38)
|
586 (37)
|
83 (40)
|
|
Median age, years (range)
|
61 (19–69)
|
73 (70–100)
|
63 (19–74)
|
77 (75–100)
|
|
ECOG performance status, n (%)
| | | | |
|
0
|
503 (39)
|
153 (32)
|
598 (38)
|
58 (28)
|
|
1
|
647 (50)
|
251 (52)
|
785 (50)
|
113 (55)
|
|
2
|
119 (9)
|
56 (12)
|
147 (9)
|
28 (14)
|
|
3
|
4 (<1)
|
11 (2)
|
11 (1)
|
4 (2)
|
|
4
|
0
|
1 (<1)
|
1 (<1)
|
0
|
|
Missing
|
24 (2)
|
8 (2)
|
29 (2)
|
3 (1)
|
|
Metastatic site, n (%)
a
| | | | |
|
Liver
|
935 (72)
|
332 (69)
|
1130 (72)
|
137 (67)
|
|
Lung
|
357 (28)
|
133 (28)
|
434 (28)
|
56 (27)
|
|
Bone
|
47 (4)
|
10 (2)
|
53 (3)
|
4 (2)
|
|
Other
|
350 (27)
|
107 (22)
|
408 (26)
|
49 (24)
|
|
No. of metastatic sites, n (%)
| | | | |
|
1
|
824 (64)
|
321 (67)
|
1007 (64)
|
138 (67)
|
|
>1
|
405 (31)
|
124 (26)
|
476 (30)
|
53 (26)
|
|
Missing
|
68 (5)
|
35 (7)
|
88 (6)
|
15 (7)
|
|
Local recurrence, n (%)
|
585 (51)
|
220 (51)
|
711 (51)
|
94 (50)
|
|
Median CEA, ng/mL (range)
|
20.9 (0–14 671)
|
20.7 (0.1–25305)
|
20.4 (0–25 305)
|
25.6 (0.1–6848)
|
|
Surgical removal of primary tumour, n (%)
|
1210 (93)
|
442 (92)
|
1464 (93)
|
188 (91)
|
|
Prior radiotherapy, %
|
18
|
14
|
18
|
12
|
|
Prior chemotherapy, %
| | | | |
|
Adjuvant
|
67
|
68
|
67
|
66
|
|
Neoadjuvant
|
11
|
11
|
10
|
12
|
|
Systolic hypertension, %
| | | | |
|
Mild
|
26
|
28
|
27
|
25
|
|
Moderate
|
6
|
8
|
6
|
10
|
|
Severe
|
1
|
1
|
1
|
1
|
|
Diaystolic hypertension, %
| | | | |
|
Mild
|
17
|
14
|
17
|
12
|
|
Moderate
|
2
|
3
|
2
|
3
|
|
Severe
|
1
|
1
|
1
|
0
|
